Beranda › Neuroblastoma › Massachusetts
Uji klinis Neuroblastoma di Massachusetts
13 studi untuk Neuroblastoma mencari peserta di lokasi di Massachusetts.
Kota di Massachusetts
Teks studi resmi (Bahasa Inggris)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 3
Hingga usia 30 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06172296MCT for the Harvard/UCSF ROBIN Center
- Brigham and Women's Hospital, Boston
Menerima peserta
Semua usia · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06000787Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Dana-Farber Cancer Institute ( Site 1013), Boston
Menerima pesertaFase 1/2
6 Months – 25 Years · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06395103B7-H3.CD28Z.CART in Solid Tumors
- Dana Farber Cancer Institite, Boston
Menerima pesertaFase 1
9 Months – 30 Years · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07358260Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 3
365 Days – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04851119SPEARHEAD-3 Pediatric Study
- Dana Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
Usia 2 hingga 21 · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05642455PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
Usia 1 hingga 30 · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT06721689NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Boston Children's Hospital, Dana-Farber Cancer Institute., Boston
Menerima pesertaFase 2
Usia 1 hingga 31 · Semua jenis kelamin · Diperbarui 20 Jul 2026 · NCT06450041Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 1
Usia 1 hingga 30 · Semua jenis kelamin · Diperbarui 14 Jul 2026 · NCT07027748Neuroblastoma Biology Study
- Children's Hospital Boston, Boston
Menerima pesertaStudi observasional
31 Days – 99 Years · Semua jenis kelamin · Diperbarui 23 Mar 2026 · NCT01587300Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- Dana-Farber Cancer Institute, Boston
Menerima peserta
Hingga usia 17 · Semua jenis kelamin · Diperbarui 10 Feb 2026 · NCT06831552Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
12 Months – 29 Years · Semua jenis kelamin · Diperbarui 26 Des 2025 · NCT06803875Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.